The findings provided fresh perspectives into the therapy of GC by demonstrating that DOT1L stimulates the progression of GC via CTNNB1 through upregulating CD44 and activating the Wnt signaling pathway. This evidence concerns the gene CTNNB1 and gastric cancer.